GlassScriptPhysician profile
Deirdre M Connolly
NPI 1124076120
$3,181.28
in general payments reported to CMS, 2019-2025
29 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $210 · 2021: $55.66 · 2022: $267 · 2023: $600 · 2024: $971 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $492.63 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $440.68 | 2019-2025 | |
| Novo Nordisk INC | $255.36 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $248.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $191.10 | 2019-2024 | Veozah |
| Lilly USA, LLC | $170.93 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $152.26 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $133.29 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Abbott Laboratories | $118.23 | 2024-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $116.80 | 2023-2025 | Rexulti |
| Abbvie INC. | $108.85 | 2023-2024 | Qulipta |
| Phathom Pharmaceuticals, INC. | $98.03 | 2024-2025 | Voquezna |
| Lundbeck LLC | $97.68 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.64 | 2019-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $57.03 | 2023 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $52.66 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $51.99 | 2019-2020 | |
| Hologic Sales and Service, LLC | $50.13 | 2024-2025 | Thinprep 2000 Processor, Aptima |
| Radius Health, INC. | $34.79 | 2024 | |
| Sanofi-Aventis U.S. LLC | $31.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.15 | 2019-2020 | |
| Sanofi Pasteur INC. | $26.63 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.40 | 2024 | Caplyta |
| Shield Therapeutics INC | $22.55 | 2023 | Accrufer |
| Collegium Pharmaceutical, INC. | $22.27 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.41 | 2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $15.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre Connolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.